WilliamLReadMD

Oncology • Atlanta, GA

Associate Professor, Hematology and Medical Oncology, Emory University School of Medicine

Join to view full profile

Dr. Read is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Read's full profile

Already have an account?

Office
1365 Clifton Rd Ne
Clinic C Second Floor
Atlanta, GA 30322
Phone+1 404-778-1900

Fax+1 404-778-5676

Education & Training

Washington University/B-JH/SLCH ConsortiumFellowship, Hematology and Medical Oncology, 1999 - 2002
Washington University/B-JH/SLCH ConsortiumResidency, Internal Medicine, 1996 - 1999
University of Nebraska College of MedicineClass of 1996

Certifications & Licensure

CA State Medical License 2003 - Present
GA State Medical License 2011 - 2025

Awards, Honors, & Recognition

Top Doctors:Southern California Castle Connolly, 2012
Super Doctor SuperDoctors.com

Clinical Trials

Phenylbutyrate and Valganciclovir in Treating Patients With Relapsed or Refractory Epstein-Barr Virus-Positive Cancer Start of enrollment: 2006 May 01
Withdrawn
Phase 2
AP5346 or Oxaliplatin in Treating Patients With Metastatic and/or Unresectable Recurrent Head and Neck Cancer Start of enrollment: 2006 May 01
Unknown status
Not Applicable
Gefitinib and PEG-Interferon Alfa-2a in Treating Patients With Unresectable or Metastatic Skin Cancer Start of enrollment: 2006 Sep 01
Unknown status
Phase 1, Phase 2
A Phase II Trial Comparing Gemcitabine and Pazopanib Versus Gemcitabine and Docetaxel for Patients With Advanced Soft Tissue Sarcoma Start of enrollment: 2012 Sep 27
Completed
Phase 2
A Study of Subcutaneous Bevacizumab in Relapsed / Progressive Glioblastoma Start of enrollment: 2014 Jan 01
Completed
Phase 2
Verteporfin for the Treatment of Recurrent High Grade EGFR-Mutated Glioblastoma Start of enrollment: 2021 Jan 15
Recruiting
Phase 1, Phase 2
Join now to see all

Publications & Presentations

PubMed

10 citations
A randomised phase II trial of a trivalent ganglioside vaccine targeting GM2, GD2 and GD3 combined with immunological adjuvant OPT-821 versus OPT-821 alone in metastat...
Evan Rosenbaum, Rashmi Chugh, Christopher W Ryan, Mark Agulnik, Mohammed M Milhem
European Journal of Cancer. 2022-11-01
1438 citations
Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial
Roger Stupp, Sophie Taillibert, Andrew A. Kanner, William L. Read, David M. Steinberg
JAMA. 2017-12-19
22 citations
Atezolizumab for Advanced Alveolar Soft Part Sarcoma.
Alice P Chen, Elad Sharon, Geraldine O'Sullivan-Coyne, Nancy Moore, Jared C Foster
The New England Journal of Medicine. 2023-09-07

Press Mentions

Research Roundup: Recent Grants and Publications for Emory Faculty and StaffJuly 15th, 2020